Intuitive Surgical

Investors are debating whether Intuitive Surgical's market valuation is justified, with commentary weighing the maker of the da Vinci surgical system's premium share price against its growth prospects in robotic surgery. The discussion forms part of broader questions about whether high-priced medical technology stocks still offer value at current levels.